Sponsor oversight of outsourced CRO work is often robust in practice but fails inspection because oversight decisions are ...

FDA seeks input on early-phase ibogaine protocols, spanning patient population selection, escalation schema with a proposed ...

Autonomous capability can expand via new tools, memory, prompts, and delegation despite unchanged models, necessitating ...

In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains why combining analog trial performance ...

In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated ...

In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the ...

In part three of her DPHARM interview, Andrea Valente, CEO of uMotif, explains why truly understanding the patient journey ...

RWE is finding a role earlier in drug development than ever before, but the data quality, integration, and organizational ...

In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is expanding endpoint selection ...

The new effort combines adaptive platform trial design, AI-enabled site activation, nationwide data infrastructure, and patient data contribution tools to reduce timelines, costs, and patient burden ...

In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, ...

Community engagement is a powerful tool but its impact depends on how it is done. When it begins early, is sustained over time, and is built through organizations and individuals communities already ...